CRISPR Therapeutics
CRSP
CRSP
253 hedge funds and large institutions have $1.92B invested in CRISPR Therapeutics in 2019 Q4 according to their latest regulatory filings, with 91 funds opening new positions, 68 increasing their positions, 52 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
2.91% more ownership
Funds ownership: 50.39% → 53.3% (+2.9%)
4% less call options, than puts
Call options by funds: $55.6M | Put options by funds: $58.2M
Holders
253
Holding in Top 10
6
Calls
$55.6M
Puts
$58.2M
Top Buyers
| 1 | +$27.4M | |
| 2 | +$25.1M | |
| 3 | +$24.4M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.2M |
| 5 |
Two Sigma Investments
New York
|
+$22.1M |
Top Sellers
| 1 | -$17.1M | |
| 2 | -$13.2M | |
| 3 | -$12.8M | |
| 4 |
AC
Armistice Capital
New York
|
-$7.07M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$6.91M |